![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TRIP6 |
Gene summary for TRIP6 |
![]() |
Gene information | Species | Human | Gene symbol | TRIP6 | Gene ID | 7205 |
Gene name | thyroid hormone receptor interactor 6 | |
Gene Alias | OIP-1 | |
Cytomap | 7q22.1 | |
Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | Q15654 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7205 | TRIP6 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.19e-18 | 4.44e-01 | 0.0155 |
7205 | TRIP6 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.05e-06 | 3.18e-01 | -0.0811 |
7205 | TRIP6 | HTA11_78_2000001011 | Human | Colorectum | AD | 5.01e-13 | 4.98e-01 | -0.1088 |
7205 | TRIP6 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.34e-06 | 4.49e-01 | -0.1207 |
7205 | TRIP6 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.45e-09 | 3.05e-01 | -0.1464 |
7205 | TRIP6 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.58e-21 | 7.68e-01 | -0.059 |
7205 | TRIP6 | HTA11_546_2000001011 | Human | Colorectum | AD | 2.53e-03 | 3.35e-01 | -0.0842 |
7205 | TRIP6 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.32e-12 | 4.15e-01 | 0.096 |
7205 | TRIP6 | HTA11_8622_2000001021 | Human | Colorectum | SER | 7.72e-05 | 4.57e-01 | 0.0528 |
7205 | TRIP6 | HTA11_10711_2000001011 | Human | Colorectum | AD | 8.38e-11 | 4.62e-01 | 0.0338 |
7205 | TRIP6 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.28e-32 | 8.03e-01 | 0.0674 |
7205 | TRIP6 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.26e-12 | 6.30e-01 | 0.0588 |
7205 | TRIP6 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.16e-18 | 4.96e-01 | 0.294 |
7205 | TRIP6 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.57e-07 | 4.31e-01 | 0.281 |
7205 | TRIP6 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.62e-14 | 6.87e-01 | 0.2585 |
7205 | TRIP6 | LZE2T | Human | Esophagus | ESCC | 9.09e-05 | 1.81e-01 | 0.082 |
7205 | TRIP6 | LZE4T | Human | Esophagus | ESCC | 4.36e-07 | 3.80e-02 | 0.0811 |
7205 | TRIP6 | LZE7T | Human | Esophagus | ESCC | 1.40e-06 | 6.58e-02 | 0.0667 |
7205 | TRIP6 | LZE8T | Human | Esophagus | ESCC | 7.43e-04 | 2.17e-01 | 0.067 |
7205 | TRIP6 | LZE20T | Human | Esophagus | ESCC | 7.60e-03 | 4.70e-02 | 0.0662 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | ![]() |
Stomach | GC | ![]() |
Stomach | CAG with IM | ![]() |
Stomach | CSG | ![]() |
Stomach | CAG | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034329 | Colorectum | AD | cell junction assembly | 136/3918 | 420/18723 | 2.02e-08 | 1.15e-06 | 136 |
GO:0150115 | Colorectum | AD | cell-substrate junction organization | 44/3918 | 101/18723 | 2.38e-07 | 9.81e-06 | 44 |
GO:0031589 | Colorectum | AD | cell-substrate adhesion | 116/3918 | 363/18723 | 4.68e-07 | 1.76e-05 | 116 |
GO:0007044 | Colorectum | AD | cell-substrate junction assembly | 41/3918 | 95/18723 | 8.20e-07 | 2.85e-05 | 41 |
GO:0007160 | Colorectum | AD | cell-matrix adhesion | 75/3918 | 233/18723 | 3.56e-05 | 6.45e-04 | 75 |
GO:0048041 | Colorectum | AD | focal adhesion assembly | 34/3918 | 87/18723 | 8.30e-05 | 1.30e-03 | 34 |
GO:00343291 | Colorectum | SER | cell junction assembly | 100/2897 | 420/18723 | 4.23e-06 | 1.61e-04 | 100 |
GO:01501151 | Colorectum | SER | cell-substrate junction organization | 34/2897 | 101/18723 | 4.46e-06 | 1.67e-04 | 34 |
GO:00070441 | Colorectum | SER | cell-substrate junction assembly | 31/2897 | 95/18723 | 2.34e-05 | 6.64e-04 | 31 |
GO:00315891 | Colorectum | SER | cell-substrate adhesion | 86/2897 | 363/18723 | 2.36e-05 | 6.64e-04 | 86 |
GO:00480411 | Colorectum | SER | focal adhesion assembly | 26/2897 | 87/18723 | 4.98e-04 | 7.08e-03 | 26 |
GO:00071601 | Colorectum | SER | cell-matrix adhesion | 53/2897 | 233/18723 | 2.10e-03 | 2.06e-02 | 53 |
GO:00343292 | Colorectum | MSS | cell junction assembly | 120/3467 | 420/18723 | 2.51e-07 | 1.07e-05 | 120 |
GO:00315892 | Colorectum | MSS | cell-substrate adhesion | 104/3467 | 363/18723 | 1.35e-06 | 4.51e-05 | 104 |
GO:01501152 | Colorectum | MSS | cell-substrate junction organization | 39/3467 | 101/18723 | 1.74e-06 | 5.60e-05 | 39 |
GO:00070442 | Colorectum | MSS | cell-substrate junction assembly | 36/3467 | 95/18723 | 7.10e-06 | 1.82e-04 | 36 |
GO:00071602 | Colorectum | MSS | cell-matrix adhesion | 65/3467 | 233/18723 | 2.77e-04 | 3.67e-03 | 65 |
GO:00480412 | Colorectum | MSS | focal adhesion assembly | 29/3467 | 87/18723 | 6.84e-04 | 7.37e-03 | 29 |
GO:015011519 | Esophagus | HGIN | cell-substrate junction organization | 24/2587 | 101/18723 | 4.85e-03 | 4.16e-02 | 24 |
GO:19012247 | Esophagus | HGIN | positive regulation of NIK/NF-kappaB signaling | 18/2587 | 69/18723 | 4.94e-03 | 4.18e-02 | 18 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046219 | Esophagus | HGIN | NOD-like receptor signaling pathway | 45/1383 | 186/8465 | 3.40e-03 | 2.54e-02 | 2.02e-02 | 45 |
hsa0462114 | Esophagus | HGIN | NOD-like receptor signaling pathway | 45/1383 | 186/8465 | 3.40e-03 | 2.54e-02 | 2.02e-02 | 45 |
hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa0462132 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa046218 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa0462113 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa0462121 | Oral cavity | LP | NOD-like receptor signaling pathway | 73/2418 | 186/8465 | 9.80e-04 | 4.53e-03 | 2.92e-03 | 73 |
hsa0462131 | Oral cavity | LP | NOD-like receptor signaling pathway | 73/2418 | 186/8465 | 9.80e-04 | 4.53e-03 | 2.92e-03 | 73 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRIP6 | SNV | Missense_Mutation | novel | c.1276N>T | p.His426Tyr | p.H426Y | Q15654 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
TRIP6 | SNV | Missense_Mutation | rs750780514 | c.892N>T | p.Arg298Cys | p.R298C | Q15654 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TRIP6 | SNV | Missense_Mutation | novel | c.778A>G | p.Thr260Ala | p.T260A | Q15654 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
TRIP6 | SNV | Missense_Mutation | rs748260838 | c.1384N>A | p.Ala462Thr | p.A462T | Q15654 | protein_coding | tolerated(0.16) | possibly_damaging(0.67) | TCGA-E9-A1RE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
TRIP6 | SNV | Missense_Mutation | c.1322C>T | p.Ser441Phe | p.S441F | Q15654 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
TRIP6 | SNV | Missense_Mutation | rs371631775 | c.341N>T | p.Ala114Val | p.A114V | Q15654 | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TRIP6 | SNV | Missense_Mutation | rs778782117 | c.893G>A | p.Arg298His | p.R298H | Q15654 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TRIP6 | SNV | Missense_Mutation | rs139848707 | c.1111N>A | p.Gly371Ser | p.G371S | Q15654 | protein_coding | tolerated(1) | benign(0.01) | TCGA-A6-A565-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unspecific | 5FU | PD |
TRIP6 | SNV | Missense_Mutation | c.1019N>T | p.Ala340Val | p.A340V | Q15654 | protein_coding | deleterious(0.01) | benign(0.027) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TRIP6 | SNV | Missense_Mutation | rs770472424 | c.1100N>C | p.Val367Ala | p.V367A | Q15654 | protein_coding | deleterious(0.04) | benign(0.148) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |